Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Presents Tougher Restrictions on Reimbursement of Vitamins
February 1, 2012
- DPJ’s PAL Subcommittee to Discuss Legal Handling of Drugs and Medical Devices
February 1, 2012
- CSIMC General Assembly Establishes Premium for Prescriptions by Generic Name
January 31, 2012
- PAFSC’s First Committee Recommends Designation of Pasireotide Pamoate as Orphan Drug
January 30, 2012
- JPO Decides Lipitor Crystal Form “Valid”, Sandoz Calls for Appeal
January 30, 2012
- PAFSC’s First Committee Recommends Approval for Zyprexa for Depression in Bipolar Disorders
January 30, 2012
- MHLW Grants Fast Track Review Status for Applications for Generic Brand Name Change
January 27, 2012
- MHLW Presents New 5-Year Plan to Promote Clinical Trials
January 27, 2012
- CSIMC Recommend Approval for Basic Proposal for FY2012 NHI Pricing; 0.86% Price Cut for Long-Listed Drugs, 0.33% for Generics
January 26, 2012
- NHI Price Reduction Method Changed for Aricept, Flolan
January 26, 2012
- Rule Review in Similar Drug Re-Pricing Yields 50 Exemptions Based on Competitiveness
January 26, 2012
- Correct Dosage, Administration for Lamictal Asked: Pharmaceuticals Safety Info
January 26, 2012
- Companies Should Be Required to File Notifications for Package Inserts: Subcommittee
January 26, 2012
- HSC Subcommittee Approves Revised Ethical GL for Genomics Research
January 26, 2012
- PMDA Considering Review Procedure Policy for IVD Agents Based on FDA Guidance Draft
January 25, 2012
- 16 APIs Including Aricept, Lyrica to Be Re-Priced for Market Expansion
January 25, 2012
- MHLW to Issue Revised Notifications in Preparation for Application to PIC/S
January 25, 2012
- Revised Basic Plan Against Cancer to Include Pediatric Cancer Measures
January 24, 2012
- Senior Vice Minister Tsuji to Actively Support Creation of 3rd-Party Organization
January 23, 2012
- Proposed Amendment of PAL Would Require Submission of Package Inserts: Mr Kikura
January 23, 2012
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…